Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CLNN

Clene Inc

Apr 15 • 04:00PM ET

0.3314

Dollar change -0.0283
Percentage change -7.87	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.55	Insider Own	47.09%	Shs Outstand	128.42M	Perf Week	-16.94%
Market Cap	42.56M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	0.42%	Shs Float	67.95M	Perf Month	-21.10%
Income	-49.50M	PEG	-	EPS next Q	-0.08	Inst Own	9.33%	Short Float	0.24%	Perf Quarter	-30.93%
Sales	0.65M	P/S	65.48	EPS this Y	35.74%	Inst Trans	11.31%	Short Ratio	0.26	Perf Half Y	-33.81%
Book/sh	0.10	P/B	3.18	EPS next Y	6.62%	ROA	-102.25%	Short Interest	0.16M	Perf Year	-69.60%
Cash/sh	0.27	P/C	1.22	EPS next 5Y	-	ROE	-595.47%	52W Range	0.25 - 1.13	Perf YTD	11.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.22%	ROI	-194.55%	52W High	-70.67%	Beta	0.51
Dividend TTM	-	Quick Ratio	1.53	Sales past 5Y	50.93%	Gross Margin	-227.37%	52W Low	32.56%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	1.53	EPS Y/Y TTM	-15.71%	Oper. Margin	-6198.78%	RSI (14)	30.16	Volatility	9.31% 7.64%
Employees	85	Debt/Eq	2.40	Sales Y/Y TTM	38.27%	Profit Margin	-7569.42%	Recom	1.00	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	0.90	EPS Q/Q	-461.70%	Payout	-	Rel Volume	1.02	Prev Close	0.36
Sales Surprise	17.24%	EPS Surprise	86.11%	Sales Q/Q	-27.35%	Earnings	Mar 13 BMO	Avg Volume	635.20K	Price	0.33
SMA20	-18.83%	SMA50	-21.75%	SMA200	-36.29%	Trades		Volume	645,286	Change	-7.87%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-04-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-18-22	Initiated	H.C. Wainwright	Buy	$16
May-02-22	Initiated	Canaccord Genuity	Buy	$10
Sep-28-21	Initiated	Oppenheimer	Outperform	$20

Mar-19-24 08:30AM	IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington (GlobeNewswire)
Mar-15-24 08:00AM	Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® (GlobeNewswire)
Mar-13-24 09:30AM	Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights (GlobeNewswire)
Mar-07-24 08:00AM	Clene to Present at the 36th Annual ROTH Conference (GlobeNewswire)
08:00AM	Loading…
Feb-29-24 08:00AM	Clene Presents Clinical Results of CNM-Au8 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024 (GlobeNewswire) -7.28%
Feb-22-24 08:00AM	Clene Reports Significant Survival Benefit With CNM-Au8 Treatment in ALS EAP Compassionate Use Programs (GlobeNewswire)
Feb-05-24 02:30PM	Clene Inc. announces positive results from CNM-Au8 results from MS trial (News Direct) -6.18%
Jan-24-24 08:30AM	Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment (NewMediaWire) +9.11%
Jan-10-24 09:00AM	Clene Announces Significant Positive Results from LTE VISIONARY-MS Trial (NewMediaWire)
Jan-08-24 07:00AM	Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8 Treatment in VISIONARY-MS Trial Long-Term Open Label Extension (GlobeNewswire) +22.07%
Jan-03-24 04:25PM	Clene's Phase 2 REPAIR-PD and REPAIR-MD Trials Support Advancement to Phase 3 (NewMediaWire)
Dec-22-23 03:00PM	Clene Announces New Data from HEALEY ALS Platform Trial (NewMediaWire) -7.94%
Dec-21-23 07:46AM	FDA unconvinced by Clene's request for ALS therapy's accelerated approval tag (FierceBiotech.com) -38.83%
07:00AM	Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8 Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension (GlobeNewswire)
07:00AM	Loading…
07:00AM	Clene Provides Update on ALS Clinical Development Meeting With FDA (GlobeNewswire)
Dec-19-23 09:00AM	How Clene CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders (NewMediaWire) +9.35%
Dec-15-23 03:00PM	Clene Lead Drug Candidate Featured in Peer-Reviewed Publication (NewMediaWire)
Dec-14-23 08:36AM	Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases (GlobeNewswire)
Dec-12-23 08:30AM	Clene's Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients (NewMediaWire) -6.45%
Dec-08-23 02:19PM	Nobel Prize in Chemistry's Spotlight on Nanotechnology Shines Light on Clene Efforts to Develop Catalytically Active Nanoparticles (NewMediaWire)
Nov-23-23 09:00AM	Clene Capitalizing on Promising Chemical and Therapeutic Properties of Nanocrystals (NewMediaWire)
Nov-14-23 08:30AM	Clene Among Grant Awardees Selected to Advance Scientific Research on ALS (NewMediaWire) -6.78%
Nov-09-23 09:00AM	Clene Announces Q3 2023 Financial Results, Operating Highlights (NewMediaWire)
Nov-07-23 08:57AM	Clene Inc (CLNN) Reports Q3 2023 Financial Results: Significant Survival Benefits and $45. ... (GuruFocus.com) +8.02%
08:00AM	Clene Reports Third Quarter 2023 Financial Results and Operating Highlights (GlobeNewswire)
Oct-31-23 08:30AM	Clene Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis (NewMediaWire)
Oct-26-23 08:30AM	Clene Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS (NewMediaWire)
Oct-19-23 08:30AM	Clene 'Innovates' Investigational Drug With Patented Nanotechnology (NewMediaWire)
Oct-17-23 08:30AM	Clene Applies Patented Nanotechnology to Development of CNM-Au8(R), Its Investigational Drug for ALS (NewMediaWire) -5.77%
09:00AM	Loading…
Oct-11-23 09:00AM	Clene CEO Featured in Latest Episode of The Bell2Bell Podcast (NewMediaWire)
Oct-06-23 02:15PM	Clene Announces $45.1M NINDS Grant (NewMediaWire)
Oct-05-23 10:00AM	National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8 Study in ALS (GlobeNewswire) +9.98%
Sep-29-23 03:00PM	Clene Investigational Drug Focus of Study Published in Peer-Reviewed Journal (NewMediaWire)
08:30AM	Clene Inc. Is 'One to Watch' (NewMediaWire)
Sep-28-23 08:00AM	Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action (GlobeNewswire) -5.30%
Sep-27-23 09:00AM	Clene Releases Significant Long-Term Survival Improvement Data from ALS Trial (NewMediaWire)
Sep-25-23 04:00PM	Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference (GlobeNewswire)
07:00AM	Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls (GlobeNewswire)
Aug-30-23 08:20AM	Clene to Present at Upcoming September Conferences (GlobeNewswire) +7.94%
Aug-29-23 07:00AM	Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up (GlobeNewswire)
Aug-14-23 08:00AM	Clene Reports Second Quarter 2023 Financial Results and Operating Highlights (GlobeNewswire)
Aug-02-23 07:00AM	Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jun-28-23 11:19AM	Insiders Pour Millions Into These 2 Strong Buy Stocks Heres Why You Might Want to Steer Toward Them Too (TipRanks) +5.14%
07:13AM	Daily Vickers Top Buyers & Sellers for 06/28/2023 (Argus Research)
Jun-26-23 08:00AM	Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCETs eClinicalMedicine (GlobeNewswire)
Jun-21-23 09:20AM	Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million (GlobeNewswire) -8.00%
07:20AM	Daily Vickers Top Buyers & Sellers for 06/21/2023 (Argus Research)
Jun-16-23 08:00AM	Clene Announces Pricing of $40 Million Public Offering (GlobeNewswire) -18.85%
Jun-15-23 04:38PM	Clene Announces Launch of Proposed Public Offering (GlobeNewswire)
04:29PM	Clenes CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial (GlobeNewswire)
07:00AM	Clene to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
May-25-23 08:00AM	Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8® in Non-Active Progressive Multiple Sclerosis (GlobeNewswire)
May-12-23 04:00PM	Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights (GlobeNewswire)
Apr-25-23 04:05PM	ALS and MS Clinical Data from Clenes CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting (GlobeNewswire)
Apr-11-23 08:00AM	Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-16-23 09:46AM	Clene Appoints Neurology Expert to Executive Team (GlobeNewswire)
Mar-13-23 07:00AM	Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights (GlobeNewswire) +7.94%
Mar-09-23 06:30AM	CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial (GlobeNewswire)
Mar-08-23 04:10PM	Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial (GlobeNewswire)
Mar-07-23 08:00AM	Clene Nanomedicine to Participate in Roths 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series (GlobeNewswire)
Mar-06-23 07:00AM	New Data Show CNM-Au8® Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial (GlobeNewswire) +6.67%
Feb-27-23 07:00AM	Clene Announces Updated VISIONARY-MS Phase 2 Trial Data Presented at 2023 ACTRIMS Forum Show CNM-Au8® Demonstrated Significant Improvements in Clinical Outcomes, Brain Structure, and Visual System (GlobeNewswire)
Feb-13-23 07:00AM	Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity (GlobeNewswire) +7.41%
Jan-11-23 08:00AM	Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23 (GlobeNewswire)
Dec-27-22 04:01PM	Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg (GlobeNewswire)
Dec-12-22 08:00AM	Clene Announces Closing of $5 Million Debt Facility from the State of Maryland (GlobeNewswire)
Nov-28-22 08:00AM	VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies (GlobeNewswire) +5.88%
Nov-07-22 08:00AM	Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights (GlobeNewswire) -12.69%
Oct-31-22 08:00AM	Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland (GlobeNewswire)
Oct-03-22 08:00AM	Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial (GlobeNewswire) -28.21%
Sep-30-22 04:12PM	Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3 (GlobeNewswire)
Sep-21-22 07:00AM	Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference (GlobeNewswire)
Aug-30-22 07:00AM	Clene to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-15-22 07:00AM	Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights (GlobeNewswire) +5.80%
07:00AM	Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis (GlobeNewswire)
Aug-12-22 04:01PM	Clene to Host VISIONARY-MS Results Call and Webcast on August 15 (GlobeNewswire)
Jul-19-22 07:00AM	Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS (GlobeNewswire)
Jul-14-22 07:00AM	Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial (GlobeNewswire) +43.40%
Jun-27-22 07:00AM	Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28 (GlobeNewswire) +6.90%
Jun-02-22 07:00AM	Clene Salutes Collaboration of ALS Community and Major League Baseball on Lou Gehrig Day (GlobeNewswire) +8.30%
Jun-01-22 07:00AM	New Data from Clenes RESCUE-ALS Study to be Presented at 2022 ENCALS Meeting (GlobeNewswire) +5.05%
May-19-22 07:30AM	Clene Receives $3 Million Loan from State of Maryland to Support Development of Commercial Manufacturing Facility (GlobeNewswire) +8.56%
May-16-22 08:00AM	Clene to Present at Upcoming Investor Conferences (GlobeNewswire)
May-09-22 08:00AM	Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights (GlobeNewswire) -13.53%
May-04-22 11:29AM	These 2 Penny Stocks Can Deliver Over 200% Gains, Says Canaccord (TipRanks) +17.60%
Apr-01-22 07:00AM	Updated Interim Data from Clene Nanomedicines RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting (GlobeNewswire) -5.08%
Mar-14-22 07:00AM	Clene Nanomedicine Presents Updated Clinical Data from Phase 2 RESCUE-ALS and REPAIR trials and Preclinical ALS data at 2022 MDA Clinical & Scientific Conference (GlobeNewswire)
Mar-11-22 07:00AM	Clene Reports Full Year 2021 Financial Results and Recent Operating Highlights (GlobeNewswire)
Mar-03-22 07:00AM	Clene Nanomedicine to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-24-22 07:00AM	Clene Nanomedicine Presents Data from Two Phase 2 Multiple Sclerosis Trials at ACTRIMS Forum 2022 (GlobeNewswire) +7.17%
Feb-18-22 07:00AM	Clene Nanomedicine to Present Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2022 (GlobeNewswire)
Feb-14-22 07:00AM	Clene Nanomedicine Provides Clinical Program Update (GlobeNewswire)
Feb-01-22 07:00AM	Clene Announces New Chief Financial Officer Morgan Brown (GlobeNewswire) +5.34%
Jan-26-22 05:14AM	Breakeven On The Horizon For Clene Inc. (NASDAQ:CLNN) (Simply Wall St.)
Jan-18-22 07:00AM	Clene Nanomedicines Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment in COVID-19 Trial (GlobeNewswire) -8.33%
Dec-15-21 07:00AM	Clene Nanomedicines Patent Portfolio Grows to More Than 150 Issued Worldwide, including Two Key Patents Now Validated Across Europe (GlobeNewswire) +8.13%
Dec-13-21 07:00AM	Clene Nanomedicines Facility Improvement Project Receives $1 Million Grant Award from the Maryland Department of Housing and Community Development (DHCD) (GlobeNewswire) +13.12%
Dec-12-21 06:34AM	Insider Buying: The Clene Inc. (NASDAQ:CLNN) Independent Chairman of the Board Just Bought 3.8% More Shares (Simply Wall St.)
Dec-10-21 07:00AM	Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in Late-Breaking Session at 32nd International Symposium on ALS/MND (GlobeNewswire)

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MATLIN DAVID J	Director	Nov 10 '23	Buy	0.41	250,002	102,501	7,043,686	Nov 13 07:48 AM
Stevens John Henry	Director	Jun 26 '23	Buy	0.80	316,455	253,164	800,204	Jun 27 02:13 PM
Etherington Robert Dee	Chief Executive Officer	Jun 26 '23	Buy	0.81	25,000	20,250	25,000	Jun 27 08:07 AM
Ugwumba Chidozie	Resigned as director 2/15/2023	Jun 16 '23	Buy	0.80	7,500,000	6,000,000	13,018,908	Sep 08 04:33 PM
Mosca Alison	Director	Jun 16 '23	Buy	0.80	2,394,375	1,915,500	3,238,375	Jun 20 11:02 AM
MATLIN DAVID J	Director	Jun 16 '23	Buy	0.80	1,500,000	1,200,000	6,793,684	Jun 20 07:57 AM
Gay Jonathon	Director	Jun 16 '23	Buy	0.80	105,625	84,500	105,625	Jun 20 09:50 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLNN

Clene Inc

Upgrade your FINVIZ experience